LONG-TERM FOLLOW-UP IN VERY ELDERLY PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB FRONTLINE
EHA Learning Center, Monica Crugnola, 181891
IMPACT OF ARTERIAL THROMBOTIC EVENTS ON THE LONG-TERM OUTCOME OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS TREATED IN FIRST-LINE WITH NILOTINIB: AN ANALYSIS OF THE GIMEMA CML WORKING PARTY
EHA Learning Center, Gabriele Gugliotta, 181892
ASSESSMENT OF CHRONIC RENAL INJURY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE RECEIVING TYROSINE KINASE INHIBITORS
EHA Learning Center, Qian Jiang, 181893
COMPARATIVE MONITORING OF MINIMAL RESIDUAL DISEASE (MRD) BY QPCR AND DIGITAL-PCR (DPCR) IN CHRONIC MYELOID LEUKEMIA PATIENTS ACHIEVING MAJOR OR DEEP MOLECULAR RESPONSE WITH TIROSIN-KINASE INHIBITORS
EHA Learning Center, Simona Bernardi, 181894
OUTCOME OF BLAST PHASE CHRONIC MYELOID LEUKEMIA (CML-BP) IN THE TYROSINE KINASE INHIBITOR ERA
EHA Learning Center, Chetasi Talati, 181895
EFFICACY OF SWITCHING TO DASATINIB IN CHRONIC MYELOID PATIENTS WITH LATE WARNING RESPONSES TO IMATINIB. STUDY OF THE ASSOCIATION OF RESPONSE TO DASATINIB TO IMMUNOLOGIC STATUS
EHA Learning Center, Juan Luis Steegmann, 181896
GENETIC PREDICTION OF INSULIN RESISTANCE IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH NILOTINIB
EHA Learning Center, Giovanni Caocci, 181897
THE EUROPE AGAINST CANCER PROTOCOL FOR BCR-ABL P210 TRANSCRIPT MEASUREMENT MAY OVERESTIMATE RESULTS FOR E13A2 VARIANT
EHA Learning Center, Michal Gniot, 181898
ESTABLISHMENT OF IN VIVO AND IN VITRO MODEL OF X-LINKED SIDEROBLASTIC ANEMIA
EHA Learning Center, Kei Saito, 181899
BENDAMUSTINE AND RITUXIMAB COMBINATION THERAPY FOR COLD AGGLUTININ DISEASE: RESULTS OF A PROSPECTIVE NORDIC TRIAL.
EHA Learning Center, Sigbjorn Berentsen, 181900
EX VIVO TREATMENT OF RED BLOOD CELLS FROM 15 PYRUVATE KINASE (PK)-DEFICIENT PATIENTS WITH AG-348, AN ALLOSTERIC ACTIVATOR OF PK-R, INCREASES ENZYMATIC ACTIVITY, PROTEIN STABILITY AND ATP LEVELS.
EHA Learning Center, Richard van Wijk, 181901
IDENTIFICATION OF NEW PATHOGENIC MUTATIONS IN PATIENTS WITH RED BLOOD CELL MEMBRANE DISORDERS USING NEXT-GENERATION SEQUENCING
EHA Learning Center, Maria Del Mar MAÑU PEREIRA, 181902
CLINICAL FOLLOW-UP OF 378 PATIENTS WITH AUTOIMMUNE HEMOLYTIC ANEMIA: PROGNOSTIC IMPACT OF HEMOGLOBIN LEVELS, AUTOANTIBODY CLASS, AND RETICULOCYTOPENIA AT ONSET ON THE RELAPSE RISK AND OUTCOME
EHA Learning Center, Bruno Fattizzo, 181903
HEME BINDS ANNEXIN-A5 DURING HEMOLYSIS AND PREVENTS ITS INTERACTION WITH CELL MEMBRANE PHOSPHATIDYLSERINE DURING SICKLE CELL DISEASE
EHA Learning Center, Sihem Sadoudi, 181904
USE OF PEGYLATED-CARBOXYHEMOGLOBIN BOVINE FOR THE TREATMENT OF SICKLE CELL DISEASE ASSOCIATED LEG ULCERS: RESULTS FROM A PHASE 2 SAFETY STUDY
EHA Learning Center, Hemant Misra, 181905
NON-RENAL DETERMINANTS OF ENDOGENOUS ERYTHROPOIETIN LEVELS IN SICKLE CELL DISEASE
EHA Learning Center, Kate Gardner, 181906
THE PHARMACOKINETICS (PK) OF GBT440 ARE SIMILAR IN ADOLESCENTS AND ADULTS WITH SICKLE CELL DISEASE (SCD)
EHA Learning Center, Carla Washington, 181907
DEVELOPMENT OF TAX-REDIRECTED T-CELL IMMUNOTHERAPY FOR ADULT T CELL LEUKEMIA
EHA Learning Center, Koji Kawamura, 181908
NHEJ-BASED GENE EDITING: A NOVEL GENE THERAPY APPROACH IN FANCONI ANEMIA HEMATOPOIETIC STEM AND PROGENITOR CELLS
EHA Learning Center, Francisco J Roman-Rodriguez, 181910
NOVEL, ENHANCED AND DUAL TARGETING CAR INVARIANT NKT CELL-BASED IMMUNOTHERAPY FOR CD1D+ B CELL MALIGNANCIES
EHA Learning Center, Antonia , 181911
A NOVEL CHIMERIC ANTIGEN RECEPTOR ENDOWS T CELLS WITH NK CELL-LIKE SPECIFICITY AND ATTACKS A WIDE RANGE OF HEMATOLOGICAL MALIGNANCIES AND CANCERS
EHA Learning Center, Yasushi Kasahara, 181912
NKP30-CAR REDIRECTED HUMAN T LYMPHOCYTES INDUCE POTENT ANTITUMOR IMMUNITY TO LEUKEMIA CELL LINES AND PATIENT-DERIVED ACUTE MYELOID LEUKEMIA IN NSG XENOGRAFT MODELS
EHA Learning Center, Udo Hartwig, 181913
PRECLINICAL TESTING OF ADOPTIVE T-CELL RECEPTOR GENE TRANSFER IN COMBINATION WITH CHECKPOINT INHIBITORS AS A NOVEL THERAPY FOR MULTIPLE MYELOMA
EHA Learning Center, Hakim Echchannaoui, 181914
EXPLORING HUMAN TCR- AND CAR-REDIRECTED INKT CELLS FOR ADOPTIVE CELLULAR THERAPY
EHA Learning Center, Udo Hartwig, 181916
SPECIFIC TARGETING OF ACUTE MYELOID LEUKEMIA BY THE USE OF ENGINEERED CIK (CYTOKINE-INDUCED KILLER) CELLS EXPRESSING THE ANTI-CD33 CHIMERIC ANTIGEN RECEPTOR (CAR).
EHA Learning Center, Maria Caterina Rotiroti, 181917
UPDATE ON THE FIRST PATIENTS WITH SEVERE HEMOGLOBINOPATHIES TREATED WITH LENTIGLOBIN GENE THERAPY
EHA Learning Center, Marina Cavazzana, 181918
A SINGLE INSTITUTIONAL EXPERIENCE OF 261 PATIENTS WITH LARGE GRANULAR LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Magali Van den Bergh, 181919
ONGOING PHASE 1/2 STUDY OF INCB050465, A SELECTIVE PI3K-DELTA INHIBITOR, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES (CITADEL-101)
EHA Learning Center, Andres Forero-Torres, 181920
PHASE IIIB RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) FOLLOWED BY LENALIDOMIDE VS. RITUXIMAB MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY NHL: ANALYSIS OF FOLLICULAR LYMPHOMA PATIENTS
EHA Learning Center, John Burke, 181921
A DOUBLE-BLIND, RANDOMIZED PHASE 3 STUDY TO COMPARE EFFICACY AND SAFETY OF CT-P10 TO INNOVATOR RITUXIMAB IN COMBINATION WITH CVP IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA
EHA Learning Center, Michinori Ogura, 181922
DURABLE DISEASE CONTROL OF EARLY MYCOSIS FUNGOIDES PATIENTS TREATED WITH LOW-DOSE INTERFERON-ALPHA2B AND PUVA
EHA Learning Center, Serena Rupoli, 181923
PHASE 3 ALCANZA STUDY OF BRENTUXIMAB VEDOTIN (BV) OR PHYSICIAN'S CHOICE (PC) OF METHOTREXATE (MTX) OR BEXAROTENE (BEX) IN CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA (CTCL):NUMBER NEEDED TO TREAT ANALYSIS
EHA Learning Center, Mehul R. Dalal, 181924
PRIMARY OCULAR ADNEXAL LYMPHOMA OF ALL HISTOLOGIC SUBTYPES: SURVIVAL OUTCOMES ANDRISK FACTORS IN LARGE COHORT OF PATIENTS AND LONG-TERM FOLLOW-UP
EHA Learning Center, Young-Woo JEON, 181925
CLONAL B-CELL LYMPHOCYTOSIS OF MARGINAL ZONE ORIGIN (CBL-MZ): A PROSPECTIVE REGISTRATIONAL STUDY ON 96 CASES
EHA Learning Center, Cristina Kalpadaki, 181926
SAFETY OF SUBCUTANEOUS ADMINISTRATION OF RITUXIMAB DURING THE FIRST-LINE TREATMENT OF PATIENTS WITH NON-HODGKIN LYMPHOMA: THE MABRELLA STUDY
EHA Learning Center, Carlos Panizo, 181927
REAL-WORLD EXPERIENCE WITH RITUXIMAB-FLUDARABINE (RF) AND DEXAMETHASONE, RITUXIMAB, CYCLOPHOSPHAMIDE (DRC) IN WALDENSTROM MACROGLOBULINEMIA : A RETROSPECTIVE STUDY FROM 163 PATIENTS
EHA Learning Center, Caroline Protin, 181928
MICAFUNGIN VERSUS LIPOSOMAL AMPHOTERICIN B FOR EMPIRICAL ANTIFUNGAL THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A RANDOMIZED CONTROLLED TRIAL
EHA Learning Center, Tatsuo Oyake, 181929
ANTIFUNGAL DRUGS INFLUENCE NEUTROPHIL EFFECTOR FUNCTIONS IN VITRO AND MODULATE PULMONARY DAMAGE IN INVASIVE ASPERGILLOSIS
EHA Learning Center, Frederic Ries, 181930
CHARACTERISTICS AND OUTCOME OF PULMONARY INFILTRATES IN ACUTE LEUKEMIA CLASSIFIED ACCORDING TO EORTC/MSG CRITERIA OF INVASIVE FUNGAL INFECTION: A PROSPECTIVE STUDY BY THE RETE EMATOLOGICA LOMBARDA
EHA Learning Center, Chiara Cattaneo, 181931
ANTIFUNGAL PROPHYLAXIS WITH CD101 IN IMMUNOSUPPRESSED MOUSE MODELS OF CANDIDIASIS, ASPERGILLOSIS, AND PNEUMOCYSTIS PNEUMONIA (PCP)
EHA Learning Center, Voon Ong, 181932
SURGICAL MANAGEMENT OF INVASIVE FUNGAL INFECTIONS IN ADULT LEUKAEMIA PATIENTS - EXPERIENCE FROM A LARGE TERTIARY CENTRE IN SOUTH-EAST ASIA
EHA Learning Center, yan chin tan, 181933
INFECTIONS IN MULTIPLE MYELOMA ARE FREQUENT AND PREDOMINANTLY CAUSED BY BACTERIA: RESULTS OF A 12-YEAR SURVEY FROM A SINGLE CENTER
EHA Learning Center, Marie VON LILIENFELD-TOAL, 181934
HUMAN L-FICOLIN POLYMORPHISMS CONTRIBUTE TO SUSCEPTIBILITY TO INFECTIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
EHA Learning Center, Ulf Schnetzke, 181935
PREDICTIVE FACTORS OF RESPONSE TO EPOETIN THETA IN CHEMOTHERAPY-INDUCED ANEMIA: A FRENCH MULTICENTER OBSERVATIONAL STUDY (PIVOINE).
EHA Learning Center, Philippe Rodon, 181936
TIMING OF DEFIBROTIDE INITIATION POST-DIAGNOSIS OF HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER PRIMARY CHEMOTHERAPY: EXPLORATORY ANALYSIS OF AN EXPANDED-ACCESS PROTOCOL
EHA Learning Center, Paul Richardson, 181937
ADAMTS-13 REGULATES NEUTROPHIL RECRUITMENT IN A MOUSE MODEL OF INVASIVE PULMONARY ASPERGILLOSIS
EHA Learning Center, Astrid Hasibeder, 181938
IDENTIFICATION OF THE SPECIFIC HEMATOPOIETIC STEM CELL POPULATIONS RESPONSIBLE FOR FAILURE TO HYPOMETHYLATING AGENTS IN MYELODYSPLASTIC SYNDROMES
EHA Learning Center, Irene Ganan-Gomez, 181939
FUNCTIONAL STUDY ON THE COOPERATION OF ASXL1 AND RUNX1 MUTATIONS FOR LEUKEMIC TRANSFORMATION
EHA Learning Center, Lee-Yung , 181940
A NOVEL MASS SPECTROMETRY METHOD REVEALS THE INTRACELLULAR PHARMACOKINETICS OF AZACYTIDINE THERAPY IN VIVO
EHA Learning Center, Ashwin , 181941
CLONAL EVOLUTION OF STAG2 AND NRAS DURING PROGRESSION FROM MDS TO SAML ASSESSED BY WHOLE-EXOME AND TARGETED-DEEP SEQUENCING
EHA Learning Center, Marta Martín Izquierdo, 181942
PROGRESSION OF MDS TO AML FEATURES GAIN OF SINGLE DRIVER MUTATIONS WITH CONSEQUENT CHANGES IN CLONAL COMPOSITION AND OCCURRENCE OF MULTIPLE CLONES WITH MUTATIONS IN IDENTICAL GENES
EHA Learning Center, Juliane Stosch, 181943
PRECLINICAL MODELING OF MYELODYSPLASTIC SYNDROMES
EHA Learning Center, Kevin Rouault-Pierre, 181944
MYELODYSPLASTIC SYNDROMES WITH IRON OVERLOAD ARE CHARACTERIZED BY A SWITCH FROM OXIDATIVE PHOSPHORYLATION TO GLYCOLYSIS AND THIS DEFECT IS PARTIALLY RESTORED BY IRON CHELATION. A FISM STUDY
EHA Learning Center, Daniela Cilloni, 181945
V-SET AND IMMUNOGLOBULIN DOMAIN-CONTAINING 4 (VSIG4) EXPRESSED ON MONOCYTES INCLUDING TUMOR-ASSOCIATED MACROPHAGES SUPPRESSED ANTITUMOR IMMUNE RESPONSES IN MYELODYSPLASTIC SYNDROMES
EHA Learning Center, Yasuko Kuribayashi-Hamada, 181946
TRANSCRIPTOME ASSESSMENT OF DNA REPAIR GENES IN CHRONIC MYELOMONOCYTIC LEUKEMIA: SYNTHETIC LETHALITY TARGETS
EHA Learning Center, Ana María , 181947
DIFFERENTIAL DIAGNOSIS BETWEEN MYELODYSPLASTIC SYNDROMES AND NON-CLONAL CYTOPENIAS BY FLOW CYTOMETRY ANALYSIS USING A MYELOID MATURATION DATABASE
EHA Learning Center, Maria Teresa Cedena, 181948
A PHASE IB STUDY EVALUATING THE SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB ALONE AND IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES
EHA Learning Center, Aaron T. Gerds, 181949
EPIGENETIC DRUG TREATMENT GLOBALLY INDUCES CRYPTIC TRANSCRIPTION START SITES ENCODED IN LONG TERMINAL REPEATS (LTRS)
EHA Learning Center, Michael Daskalakis, 181950
LYMPHOPENIA IS AN INDEPENDENT RISK-FACTOR IN PATIENTS WITH LOW-RISK MDS ACCORDING TO THE IPSS-R
EHA Learning Center, Tobias Silzle, 181951
IMPACT OF MARROW COMPLETE RESPONSE IN THE NATURAL HISTORY OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) TREATED WITH HYPOMETHYLATING AGENTS
EHA Learning Center, Ana Alfonso Pierola, 181952
LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS): LONG-TERM RESULTS FROM PHASE 2 PACE-MDS STUDY
EHA Learning Center, Aristoteles Giagounidis, 181953
RATE AND CAUSES OF 5-AZACYTIDINE DISCONTINUATION AND SUBSEQUENT THERAPEUTIC OPTIONS IN 418 MDS PATIENTS FROM THE ITALIAN MDS REGISTRY OF FONDAZIONE ITALIANA SINDROMI MIELODISPLASTICHE (FISM)
EHA Learning Center, Marino Clavio, 181954
COMBINATION OF DEEP PHENOTYPING AND TARGETED NEXT GENERATION SEQUENCING AS A DIAGNOSTIC TOOL IN CHILDREN WITH SUSPECTED MDS
EHA Learning Center, Eleni Louka, 181955
OUTCOMES IN PATIENTS ALLOCATED TO NO-ASCT BASED ON DEPTH OF RESPONSE: INITIAL RESULTS OF A PHASE 2 TRIAL ASSESSING THE IMPACT OF MINIMAL RESIDUAL DISEASE (MRD) IN PATIENTS WITH DEFERRED ASCT (PADIMAC)
EHA Learning Center, Kwee Yong, 181956
PROPORTION AND COMPOSITION OF BONE MARROW LYMPHOCYTE POOL AT BASELINE CORRELATES WITH OUTCOME IN MM PATIENTS AFTER RVD AND ASCT
EHA Learning Center, Sini Luoma, 181957
VALUE OF THE 18F-FDG PET-CT IN THE IDENTIFYING BONE INVOLVEMENT EITHER AT DIAGNOSIS OR DURING FOLLOW-UP OF PATIENTS AFFECTED BY MULTIPLE MYELOMA.
EHA Learning Center, sara galimberti, 181958
INITIAL PHASE 2 RESULTS OF IBRUTINIB COMBINED WITH BORTEZOMIB/DEXAMETHASONE IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA
EHA Learning Center, Roman Hajek, 181959
PROGNOSTIC SIGNIFICANCE OF CLONAL CIRCULATING PLASMA CELLS BY MULTI-PARAMETRIC FLOW CYTOMETRY IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION
EHA Learning Center, Surbhi Sidana, 181960
RENAL IMPAIRMENT IN MYELOMA - PATIENT CHARACTERISTICS, TREATMENT MODALITIES, STEM CELL TRANSPLANT & OUTCOMES FROM THE AUSTRALIAN AND NEW ZEALAND MYELOMA REGISTRY
EHA Learning Center, Joy Ho, 181961
VENETOCLAX AS TARGETED THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Learning Center, Shaji K Kumar, 181962
AN OPEN-LABEL, PHASE 1B STUDY (MMY1001) OF DARATUMUMAB COMBINED WITH CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRD) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)
EHA Learning Center, Saad Z. Usmani, 181963
GENE EXPRESSION CLASSIFIER EMC92/SKY92 AND REVISED ISS ROBUSTLY IDENTIFY HIGH-RISK MULTIPLE MYELOMA IN ELDERLY PATIENTS OF THE HOVON-87/NMSG-18 STUDY
EHA Learning Center, R Kuiper, 181964
MULTIPLE MYELOMA AND COMORBIDITY: A POPULATION-BASED STUDY
EHA Learning Center, Ingigerdur Solveig Sverrisdottir, 181965
DETECTION OF NEW EMERGING CLONES DURING TREATMENT BY NGS ALLOWS A BETTER RISK PREDICTION ON MULTIPLE MYELOMA PATIENTS
EHA Learning Center, Beatriz Sanchez-Vega, 181966
FINAL RESULTS OF PHASE (PH) 1/2 STUDY OF CARFILZOMIB, POMALIDOMIDE, AND DEXAMETHASONE (KPD) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A MULTI-CENTER MMRC STUDY
EHA Learning Center, Andrzej J. Jakubowiak, 181967
PANOBINOSTAT INDUCES CD38 UPREGULATION AND AUGMENTSTHE ANTI-MYELOMA EFFICACY OF DARATUMUMAB
EHA Learning Center, Estefania Garcia-Guerrero, 181968
BCL2 EXPRESSION IS A POTENTIAL PREDICTIVE BIOMARKER OF RESPONSE TO VENETOCLAX IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Learning Center, Jeremy Ross, 181969
THE IMPACT OF THE INTRODUCTION OF BORTEZOMIB ON DIALYSIS INDEPENDENCE IN MULTIPLE MYELOMA PATIENTS WITH RENAL FAILURE: A NATIONWIDE DUTCH POPULATION-BASED STUDY
EHA Learning Center, Berdien Oortgiesen, 181970
TREATMENT WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA AND LIGHT CHAIN (AL) AMYLOIDOSIS
EHA Learning Center, Paolo Milani, 181971
MYOCARDIAL UPTAKE OF 99MTC-DPD IN PATIENTS WITH AL AMYLOIDOSIS
EHA Learning Center, Carlos de Miguel Jiménez, 181972
WHEN PERFORMANCE OF CYTOGENETICS MATTERS: A POPULATION-BASED STUDY IN THE NETHERLANDS ON NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
EHA Learning Center, Mirian Brink, 181973
AN UPDATED ADJUSTED COMPARISON SUGGESTS DARATUMUMAB IS ASSOCIATED WITH PROLONGED SURVIVAL COMPARED WITH STANDARD OF CARE THERAPIES IN HEAVILY PRE-TREATED AND HIGH REFRACTORY MULTIPLE MYELOMA PATIENTS
EHA Learning Center, Shaji K. Kumar, 181974
PREDICTORS OF EARLY DEATH RELATED TO ACTIVE MULTIPLE MYELOMA IN ELDERLY PATIENTS RECEIVING OPTIMIZED FRONTLINE TREATMENT COMBINATIONS
EHA Learning Center, Paula Rodriguez-Otero, 181975
MPL ACTIVATION DIRECTLY INDUCES FIBROCYTE DIFFERENTIATION TO CAUSE MYELOFIBROSIS
EHA Learning Center, Takaaki Maekawa, 181976
ENGRAFTMENT OF PRIMARY MYELOFIBROSIS BONE MARROW-DERIVED CD14+ MONOCYTES IN NOD-SCID- MICE
EHA Learning Center, Taghi Manshouri, 181977
ESTABLISHMENT OF AN IN VITRO MODEL FOR THE SKEWED MEGAKARYOPOIESIS BY CALRETICULIN MUTATION IN HUMAN CELLS
EHA Learning Center, Hiraku Takei, 181978
QUANTITATIVE PROTEOME HETEROGENEITY IN MYELOPROLIFERATIVE NEOPLASM SUBTYPES AND ASSOCIATION WITH JAK2 MUTATION STATUS
EHA Learning Center, Nuria Socoro Yuste, 181979
THE NOVEL SWITCH CONTROL INHIBITOR DCC-2618 COUNTERACTS GROWTH AND SURVIVAL OF VARIOUS NEOPLASTIC CELLS, INCLUDING MAST CELLS, EOSINOPHILS, AND MONOCYTES, IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS
EHA Learning Center, Mathias Schneeweiss, 181980
DISTRIBUTION OF MUTATIONS IN DRIVER AND NON-DRIVER GENES ACCORDING TO CLONAL HEMATOPOIESIS IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA
EHA Learning Center, Alicia Senín, 181981
RUXOLITINIB/NILOTINIB/PREDNISOLONE COMBINATION: A PROMISING NOVEL TREATMENT FOR MYELOFIBROSIS
EHA Learning Center, Joaquin Martinez-Lopez, 181982
INTERLABORATORY ASSESSMENT OF MUTATION DETECTION IN MYELOID MALIGNANCIES BY TARGETED NEXT-GENERATION SEQUENCING
EHA Learning Center, Maria Concepcion Fernandez, 181983
METHYLATION AGE IN MPN PATIENTS AS A CORRELATE FOR DISEASE STATUS, ALLELE BURDEN AND THERAPEUTIC RESPONSE
EHA Learning Center, Suzanne McPherson, 181984
ELUCIDATING THE AGE INDUCED HEMATOPOIETIC CELL-INTRINSIC AND EXTRINSIC MECHANISMS IN MYELOPROLIFERATIVE NEOPLASM INITIATION AND PROGRESSION
EHA Learning Center, Tata Nageswara Rao, 181985
PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT), INCLUDING RUXOLITINIB, IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF) AND BASELINE THROMBOCYTOPENIA: FOCUS ON ANEMIA IN THE PHASE 3 PERSIST-2 TRIAL
EHA Learning Center, Moshe Talpaz, 181986
COMBINATION THERAPY OF POMALIDOMIDE PLUS RUXOLITINIB IN MYELOFIBROSIS:RESULTS FROM COHORT 1 OF THE MPNSG-0212 TRIAL (NCT01644110)
EHA Learning Center, Frank Stegelmann, 181987
PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT), IN PATIENTS WITH MYELOFIBROSIS (MF) AND BASELINE (BL) THROMBOCYTOPENIA: FOCUS ON RUXOLITINIB (RUX)-TREATED PATIENTS IN THE PHASE 3 PERSIST-2 TRIAL
EHA Learning Center, Claire Harrison, 181988
SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN ELDERLY PATIENTS (≥ 75 YEARS) WITH MYELOFIBROSIS (MF): AN ANALYSIS FROM THE PHASE 3B, EXPANDED-ACCESS JUMP STUDY
EHA Learning Center, Pia Raanani, 181989
PROGNOSTIC RISK MODELS FOR TRANSPLANT DECISION-MAKING IN MYELOFIBROSIS
EHA Learning Center, Juan-Carlos Hernandez-Boluda, 181990
LEUKEMIC TRANSFORMATION AND SECOND CANCERS IN 3649 HIGH RISK ET PATIENTS IN THE EXELS STUDY
EHA Learning Center, Gunnar Birgegard, 181991
EPIDEMIOLOGY, OUTCOME AND RISK FACTORS FOR INFECTIOUS COMPLICATIONS IN MF PATIENTS RECEIVING RUXOLITINIB. A MULTICENTER STUDY ON 373 PATIENTS
EHA Learning Center, Nicola Polverelli, 181992